Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Prime Medicine Inc (NASDAQ: PRME) closed the day trading at $1.30 down -1.52% from the previous closing price of $1.32. In other words, the price has decreased by -$1.52 from its previous closing price. On the day, 1.39 million shares were traded.
Ratios:
For a better understanding of PRME, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.78 and its Current Ratio is at 4.78. In the meantime, Its Debt-to-Equity ratio is 1.13 whereas as Long-Term Debt/Eq ratio is at 1.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on December 10, 2024, initiated with a Mkt Outperform rating and assigned the stock a target price of $10.
On May 20, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.
Citigroup Upgraded its Neutral to Buy on May 16, 2024, while the target price for the stock was maintained at $10.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 44.29 while its Price-to-Book (P/B) ratio in mrq is 1.59.
Stock Price History:
Over the past 52 weeks, PRME has reached a high of $8.27, while it has fallen to a 52-week low of $1.12. The 50-Day Moving Average of the stock is -24.70%, while the 200-Day Moving Average is calculated to be -58.41%.
Shares Statistics:
A total of 131.16M shares are outstanding, with a floating share count of 51.97M. Insiders hold about 60.42% of the company’s shares, while institutions hold 28.93% stake in the company.
